Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.
Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, Aso M, Kikuchi H, Nakamura A, Sekikawa M, Yoshiike F, Kitamura Y, Kimura N, Hachiya T, Tsurumi K, Agatsuma T, Megumi F, Nakamura K, Jingu D, Yamamoto H, Kosaka M, Yokouchi H. Tateishi K, et al. Among authors: yokouchi h. Jpn J Clin Oncol. 2024 Dec 4:hyae168. doi: 10.1093/jjco/hyae168. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39656678
Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301).
Hashimoto K, Morinaga D, Asahina H, Ishidoya M, Kikuchi H, Yokouchi H, Harada T, Honjo O, Shigaki R, Takashina T, Fujita Y, Takahashi M, Kawai Y, Kida R, Ito K, Sukoh N, Takahashi A, Hommura F, Ohhara Y, Furuta M, Konno S, Hosomi Y, Oizumi S; Hokkaido Lung Cancer Clinical Study Group Trial. Hashimoto K, et al. Among authors: yokouchi h. JTO Clin Res Rep. 2024 Sep 7;5(11):100715. doi: 10.1016/j.jtocrr.2024.100715. eCollection 2024 Nov. JTO Clin Res Rep. 2024. PMID: 39403627 Free PMC article.
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.
Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M. Morgensztern D, et al. Among authors: yokouchi h. Clin Cancer Res. 2024 Nov 15;30(22):5042-5052. doi: 10.1158/1078-0432.CCR-24-1547. Clin Cancer Res. 2024. PMID: 39287821 Free PMC article. Clinical Trial.
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
Furuta M, Horinouchi H, Yokota I, Yamaguchi T, Itoh S, Fukui T, Iwashima A, Sugisaka J, Miura Y, Tanaka H, Miyawaki T, Yokouchi H, Miura K, Saito R, Saito G, Kamoshida T, Uchinami Y, Kato T, Kobayashi K, Asahina H. Furuta M, et al. Among authors: yokouchi h. Cancer Sci. 2024 Nov;115(11):3705-3717. doi: 10.1111/cas.16340. Epub 2024 Sep 15. Cancer Sci. 2024. PMID: 39278260 Free PMC article.
CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy.
Yaga M, Hasegawa K, Ikeda S, Matsubara M, Hiroshima T, Kimura T, Shirai Y, Tansri W, Uehara H, Tachikawa M, Okairi Y, Sone M, Mori H, Kogue Y, Akamine H, Okuzaki D, Kawagishi K, Kawanaka S, Yamato H, Takeuchi Y, Okura E, Kanzaki R, Okami J, Nakamichi I, Nakane S, Kobayashi A, Iwazawa T, Tokunaga T, Yokouchi H, Yano Y, Uchida J, Mori M, Komuta K, Tachi T, Kuroda H, Kijima N, Kishima H, Ichii M, Futami S, Naito Y, Shiroyama T, Miyake K, Koyama S, Hirata H, Takeda Y, Funaki S, Shintani Y, Kumanogoh A, Hosen N. Yaga M, et al. Among authors: yokouchi h. Sci Rep. 2024 Aug 2;14(1):17917. doi: 10.1038/s41598-024-68779-9. Sci Rep. 2024. PMID: 39095551 Free PMC article.
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H. Ikezawa Y, et al. Among authors: yokouchi h. Cancer Med. 2024 Jul;13(14):e70036. doi: 10.1002/cam4.70036. Cancer Med. 2024. PMID: 39030894 Free PMC article.
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
Okahisa M, Udagawa H, Matsumoto S, Kato T, Yokouchi H, Furuya N, Kanemaru R, Toyozawa R, Nishiyama A, Ohashi K, Miyamoto S, Nishino K, Nakamura A, Iwama E, Niho S, Oi H, Sakai T, Shibata Y, Izumi H, Sugiyama E, Nosaki K, Umemura S, Zenke Y, Yoh K, Kah Mun Low G, Zhuo J, Goto K. Okahisa M, et al. Among authors: yokouchi h. Lung Cancer. 2024 May;191:107798. doi: 10.1016/j.lungcan.2024.107798. Epub 2024 Apr 23. Lung Cancer. 2024. PMID: 38669727
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.
Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, Shoda H, Mamesaya N, Miyata Y, Okamoto T, Okishio K, Oki M, Sakairi Y, Chen-Yoshikawa TF, Aoki T, Ohira T, Matsumoto I, Ueno K, Miyazaki T, Matsuguma H, Yokouchi H, Otani T, Ito A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Okamoto I, Nakagawa K, Takeda M. Kanemura H, et al. Among authors: yokouchi h. JTO Clin Res Rep. 2024 Mar 8;5(4):100658. doi: 10.1016/j.jtocrr.2024.100658. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38651033 Free PMC article.
325 results